Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

NASDAQ:CAPR - Nasdaq - US14070B3096 - Common Stock - Currency: USD

15.07  -0.11 (-0.72%)

After market: 15.14 +0.07 (+0.46%)

Fundamental Rating

3

Overall CAPR gets a fundamental rating of 3 out of 10. We evaluated CAPR against 572 industry peers in the Biotechnology industry. CAPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CAPR is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAPR has reported negative net income.
CAPR had a negative operating cash flow in the past year.
CAPR had negative earnings in each of the past 5 years.
In the past 5 years CAPR reported 4 times negative operating cash flow.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

CAPR has a Return On Assets (-36.70%) which is in line with its industry peers.
CAPR's Return On Equity of -49.97% is fine compared to the rest of the industry. CAPR outperforms 66.19% of its industry peers.
Industry RankSector Rank
ROA -36.7%
ROE -49.97%
ROIC N/A
ROA(3y)-48.11%
ROA(5y)-50.51%
ROE(3y)-136.19%
ROE(5y)-113.74%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CAPR has more shares outstanding
Compared to 5 years ago, CAPR has more shares outstanding
Compared to 1 year ago, CAPR has an improved debt to assets ratio.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

CAPR has an Altman-Z score of 13.56. This indicates that CAPR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CAPR (13.56) is better than 89.20% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that CAPR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.05, CAPR is not doing good in the industry: 62.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 13.56
ROIC/WACCN/A
WACC10.71%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 4.19 indicates that CAPR has no problem at all paying its short term obligations.
CAPR's Current ratio of 4.19 is in line compared to the rest of the industry. CAPR outperforms 47.96% of its industry peers.
A Quick Ratio of 4.19 indicates that CAPR has no problem at all paying its short term obligations.
The Quick ratio of CAPR (4.19) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 4.19
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.62% over the past year.
The Revenue has grown by 65.21% in the past year. This is a very strong growth!
Measured over the past years, CAPR shows a very strong growth in Revenue. The Revenue has been growing by 72.05% on average per year.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52%
Revenue 1Y (TTM)65.21%
Revenue growth 3Y333.07%
Revenue growth 5Y72.05%
Sales Q2Q%-63.43%

3.2 Future

Based on estimates for the next years, CAPR will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.39% on average per year.
Based on estimates for the next years, CAPR will show a very strong growth in Revenue. The Revenue will grow by 69.00% on average per year.
EPS Next Y-50.07%
EPS Next 2Y-7.35%
EPS Next 3Y35.37%
EPS Next 5Y8.39%
Revenue Next Year-20.3%
Revenue Next 2Y18.05%
Revenue Next 3Y68.13%
Revenue Next 5Y69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CAPR's earnings are expected to grow with 35.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.35%
EPS Next 3Y35.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (2/4/2025, 8:00:02 PM)

After market: 15.14 +0.07 (+0.46%)

15.07

-0.11 (-0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners19.93%
Inst Owner Change0.82%
Ins Owners1.59%
Ins Owner Change18.9%
Market Cap685.23M
Analysts84.62
Price Target42.11 (179.43%)
Short Float %20.04%
Short Ratio6.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.18%
Min EPS beat(2)-3.97%
Max EPS beat(2)3.61%
EPS beat(4)2
Avg EPS beat(4)-22.58%
Min EPS beat(4)-168.17%
Max EPS beat(4)78.21%
EPS beat(8)6
Avg EPS beat(8)-5.22%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-15.79%
Min Revenue beat(2)-37.86%
Max Revenue beat(2)6.27%
Revenue beat(4)2
Avg Revenue beat(4)-17.55%
Min Revenue beat(4)-50.41%
Max Revenue beat(4)11.8%
Revenue beat(8)6
Avg Revenue beat(8)2423.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.7%
EPS NQ rev (1m)3.07%
EPS NQ rev (3m)-75.55%
EPS NY rev (1m)0.78%
EPS NY rev (3m)6.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.5
P/FCF N/A
P/OCF N/A
P/B 10.04
P/tB 10.04
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.51
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.7%
ROE -49.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.11%
ROA(5y)-50.51%
ROE(3y)-136.19%
ROE(5y)-113.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.76%
Cap/Sales 6.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 4.19
Altman-Z 13.56
F-Score4
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)435.17%
Cap/Depr(5y)339.68%
Cap/Sales(3y)213.3%
Cap/Sales(5y)163.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52%
EPS Next Y-50.07%
EPS Next 2Y-7.35%
EPS Next 3Y35.37%
EPS Next 5Y8.39%
Revenue 1Y (TTM)65.21%
Revenue growth 3Y333.07%
Revenue growth 5Y72.05%
Sales Q2Q%-63.43%
Revenue Next Year-20.3%
Revenue Next 2Y18.05%
Revenue Next 3Y68.13%
Revenue Next 5Y69%
EBIT growth 1Y-21.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-74.18%
EBIT Next 3Y20.95%
EBIT Next 5YN/A
FCF growth 1Y-1141.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-694.44%
OCF growth 3YN/A
OCF growth 5YN/A